Non-invasive Gas Jet In-Vivo Profile Dosimetry for Particle Beam Therapy (JetDose)

用于粒子束治疗的非侵入性气体喷射体内轮廓剂量测定 (JetDose)

• 批准号: ST/W002159/1
• 负责人: Carsten Welsch
• 金额: $ 34.36万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=ST%2FW002159%2F1
• 关键词: Non; invasive; Gas; Jet; Vivo

In hadron beam therapy, knowledge of the detailed beam properties is essential to ensure effective dose delivery to the patient. Clinical settings currently implement interceptive ionization chambers which require daily calibration and suffer from slow response times. With new and emerging treatment techniques using ultra high dose rates, there is a demand for the development of novel beam monitors, which are fast, non-invasive and calibration-free. Current methods to carry out this characterization require multiple systems each imparting a slight disturbance to the particle beam as it passes by. This disturbance can alter the intended transverse dose profile of the beam, ultimately creating slight deviations from a patient's treatment plan. QA methods are mostly disruptive measurements and do not allow treatment to take place at all whilst they are being conducted.JetDose will develop a new in-vivo dosimetry system based on the re-application of technologies pioneered by the proposer's group. The underpinning technology was originally developed for use with low energy antiproton beams and most recently adapted for gas jet profiling for the high luminosity upgrade of the Large Hadron Collider at CERN. In this system, a supersonic gas jet is fired across the high intensity proton beam at the LHC. The gas molecules have little-to-no effect on the proton beam, however the proton beam excites the gas molecules; this excitation can be imaged, which is turn provides a complete non-invasive two-dimensional profile image of the proton beam. JetDose will redirect this technology at the medical accelerator sector, by optimizing it for the different challenges found in a treatment facility. The non-invasive means of producing a profile image will allow the monitor to be run online alongside treatment operation. As the intensity in the images directly depends upon the beam intensity, and therefore the dose, an image collected with this system provides an in-vivo dose map of the beam being delivered to the patient.The focus of the project will be the design, development, and testing of an optimized medical version of the system with established clinical and business partners. Testing and optimization will be done in close collaboration with long-standing research partners Clatterbridge Cancer Centre and Fondazione CNAO in Italy. The design, development, and future commercialization will be conducted in collaboration with the UK-based accelerator beam diagnostics company D-Beam Ltd, STFC CERN BIC graduate and recently identified as an STFC IAA success story. Commercialization plans will be progressed with leading OEM manufacturer IBA. JetDose will produce a novel monitoring system which addresses the growing need for in-vivo dosimetry in medical facilities across the world. This technology also shows good promise for application at other high intensity, high energy particle accelerators and this wider market will be assessed as part of the business plan that will be developed.

在强子梁治疗中，对详细梁特性的了解对于确保有效剂量递送给患者至关重要。临床环境目前实施截然的电离室，需要每天校准，并且响应时间缓慢。使用超高剂量速率的新型和新兴的治疗技术，需要开发新型束监测器，这些新型束监测器是快速，非侵入性且无校准的。当前执行此特征的方法需要多个系统，每个系统都会在粒子梁通过时略有干扰。这种干扰可以改变梁的预期横向剂量，最终与患者的治疗计划产生略有偏差。质量检查方法主要是破坏性的测量，并且在进行时根本不允许进行治疗。Jetdose将基于提议者组对技术的重新应用开发一种新的体内剂量学系统。该基础技术最初是为低能抗蛋白束开发的，最近适用于CERN大型强子对撞机的高光度升级。在该系统中，在LHC处的高强度质子束上发射了超音速燃气射流。气体分子对质子束几乎没有影响，但是质子束会激发气体分子。可以成像这种激发，转弯提供了质子束的完整的非侵入性二维轮廓图像。 Jetdose将通过在治疗机构中的不同挑战中优化医疗加速器部门将这项技术重定向。生产个人资料图像的非侵入性手段将允许监视器与治疗操作一起在线运行。由于图像中的强度直接取决于光束强度，因此，使用该系统收集的图像提供了将梁的体内剂量图提供给患者。测试和优化将与长期的研究合作伙伴Clatterbridge Cancer Center和意大利的Fondazione CNAO密切合作。设计，开发和未来的商业化将与总部位于英国的加速器Beam Diagnostics Company D-Beam Ltd，STFC CERN BIC毕业生合作进行，最近被确定为STFC IAA成功案例。商业化计划将与领先的OEM制造商IBA进行。 JetDose将生产出一种新型的监测系统，以解决全球医疗设施中对体内剂量测定的日益增长的需求。该技术还显示出在其他高强度，高能量粒子加速器的应用方面的良好希望，并且将评估这个更广泛的市场，作为将要制定的业务计划的一部分。